A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study.
The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and
recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days
every 3 weeks (this is considered as 1 cycle) to subjects with advanced malignant solid
tumors or lymphoma.